Compositions and methods for the treatment of coenzyme q10 deficiency

WO2024218722A3PCT designated stage expired Publication Date: 2024-11-28VELLPHARM CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/053816
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-20
Filing Date
2024-04-19
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Coenzyme Q10 has low aqueous solubility and bioavailability due to its water-insoluble nature, leading to high oral doses and associated gastrointestinal side effects, as it is poorly absorbed when administered orally, which limits its therapeutic effectiveness in treating conditions like heart failure.

Method used

Compositions comprising coenzyme Q10 combined with water-soluble excipients such as HPMC, PEG, docusate sodium, poloxamer, and polysorbate, which enhance the dissolution rate of coenzyme Q10 in an aqueous medium, allowing for lower administration amounts and improved bioavailability.

Benefits of technology

The enhanced dissolution rates of coenzyme Q10 in these compositions enable therapeutic effects with reduced side effects by allowing lower doses to achieve effective plasma concentrations, improving absorption and reducing gastrointestinal toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

The disclosure is directed to compositions comprising coenzyme Q10 and a water soluble excipient and methods of treating coenzyme Q10 deficiency in a subject comprising orally administering said composition. The composition may be in the form of a solid or liquid dosage such as spheres, granules, tablets, capsules, oral solution and soft capsules to be administered orally. The composition may comprise a mixture of coenzyme Q10 and a binder coating on a core, wherein the core comprises sugar, microcrystalline cellulose or a mixture thereof. The composition is an immediate-release formulation with high dissolution in an aqueous medium.
Need to check novelty before this filing date? Find Prior Art

Description

Compositions and Methods for the Treatment of Coenzyme Q10 DeficiencyFIELD OF THE INVENTION

[0001] The present invention broadly relates to compositions comprising coenzyme Q10 and a water soluble excipient, such as, for example, PEG, polysorbate, docusate sodium, poloxamer, organic acid or HPMC. The invention also broadly relates to methods of treating coenzyme Q10 deficiency in a subject by the invention.CROSS REFERENCE TO RELATED APPLICATION

[0002] This application claims the benefit of Australian Provisional Application No. 2023901172 filed on 20 April 2024, the entire content of which is incorporated by reference herein.BACKGROUND OF THE INVENTION

[0002] Ubiquinone, also known as coenzyme Q10 (abbreviated as CoQw), is a lipid-soluble benzoquinone and is water-insoluble. Coenzyme Q10 is involved in electron transport in mitochondria. Coenzyme Q10 is naturally-occurring in the majority of aerobic organisms, ranging from bacteria to plants and animals. In mammals, coenzyme Q10 can be found in every organ. Most foods also contain coenzyme Q10. Vegetable oil and meat typically have higher concentrations of coenzyme Q10 than dairy products.

[0003] The solubility of coenzyme Q10 is 0.239 mg / mL, which means that to dissolve 150 mg of coenzyme Q10, more than 500 mL of water is required. However, it is difficult for a healthy human to retain 500 mL of water in the stomach for more than 10 minutes, as the water will pass from the stomach through the digestive system.

[0004] The pKa of coenzyme Q10 is -4.7. In order for any drug to be absorbed it must be solubilised at the site of absorption. Various techniques are used for the enhancement of the solubility of coenzyme Q10, including physical and chemical modifications of the drug, or other methods such as particle size reduction, crystal engineering, salt formation, solid dispersion, surfactant use, complexation, amongst others. Oral bioavailability depends on several factors including, but not limited to, aqueous solubility, drug permeability, dissolution rate, first-pass metabolism and presystemic metabolism. The most frequent causes of low oral bioavailability are attributed to poor solubility and low permeability of the drug. The term "soluble" can also be used to describe materials that form colloidal suspensions of very fine solid particles in a liquid.

[0005] There are many strengths of ubiquinone or coenzyme Q10 formulations on the market, formulated for different modes of administration, however, all have the disadvantage of low dissolution in an aqueous medium.

[0006] Coenzyme Q10 is water-insoluble and is poorly absorbed when administered orally. Consequently, high oral doses are often required in order for the plasma concentration of coenzyme Q10 to reach a therapeutically effective level. This leads to a high concentration of coenzyme Q10 in the alimentary system which induces side effects. The poor absorption leads to inadequate and variable bioavailability and gastrointestinal mucosal toxicity.

[0007] The solubility of a water-insoluble drug is often related to drug particle size - as a particle becomes smaller, the surface area to volume ratio increases. A larger surface area allows greater interaction with the solvent, which increases the solubility of the drug in water.

[0008] Coenzyme Q10 is indicated for the treatment of heart failure. In a 2017 meta-analysis, administration of 30-100 mg / day of coenzyme Q10 was shown to result in 31% lower mortality. Exercise capacity was also increased. A 2018 meta-analysis concluded that there was preliminary evidence for oral coenzyme Q10 reducing statin-associated muscle symptoms, including muscle pain, muscle weakness, muscle cramps and muscle tiredness.

[0009] Coenzyme Q10 has a chemical formula of C59H90O4 and molar mass of 863.4 g / mol. Coenzyme Q10 has a yellow or orange appearance and is a solid at room temperature. Coenzyme Q10 is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP. 95% of the human body's energy is generated in this way. There are three redox states of coenzyme Q10: fully oxidized (referred to as ubiquinone or coenzyme Q10), semiquinone (also referred to as ubisemiquinone), and fully reduced (referred to as ubiquinol).

[0010] Generally, coenzyme Q10 is well tolerated. However, some adverse effects, largely gastrointestinal, are reported with very high intakes of coenzyme Q10. The most common side effects are gastrointestinal symptoms including nausea, vomiting, appetite suppression, abdominal pain, rashes, and headaches.

[0011] The strength of coenzyme Q10 formulations on the market is in the range from 5 to 600 mg per capsule and the dosage is once or twice daily, as needed. Different manufacturers provide different strengths of coenzyme Q10 and the bioavailability of the preparations may vary.

[0012] Coenzyme Q10 is also used as a dietary supplement and can be prescribed or recommended by medical professional for preventing or treating the symptoms of heart failure.

[0013] There is a need for new formulations of coenzyme Q10 with higher dissolution rates that will allow a lower administration amount of coenzyme Q10, thereby reducing the risk or severity of side effects.SUMMARY OF THE INVENTION

[0014] The present invention relates generally to compositions comprising coenzyme Q10 and a water soluble excipient, and methods of treating coenzyme Q10 deficiency.

[0015] In one aspect, the present invention provides a composition comprising coenzyme Q10 and one or more water soluble excipients selected from HPMC, PEG, docusate sodium, poloxamer, organic acid and polysorbate, wherein the composition has a dissolution amount of coenzyme Q10 in an aqueous medium of greater than 60%.

[0016] In preferred embodiments, the composition has a dissolution amount of coenzyme Q10 of greater than 60%, 70%, 80%, or 90%, in 1000 mL of an aqueous medium of 0.5% Triton of pH 4.5.

[0017] In preferred embodiments, the composition is in the form of spheres comprising coenzyme Q10, a binder comprising HPMC of low molecular mass and a core comprising one or more excipients.

[0018] In preferred embodiments, the HPMC is of a molecular mass equal to or lower than 26,000 g / mol.

[0019] In preferred embodiments, the composition comprises a HPMC and coenzyme Q10 mixture coating on the surface of the core, wherein the core comprises sugar, microcrystalline cellulose or a mixture thereof.

[0020] In preferred embodiments, the core comprises one or more of sugar, microcrystalline cellulose, lactose, starch, mannitol, sorbitol, fructose- 1,6-diphosphate, and cross-linked povidone, or a mixture thereof.

[0021] In preferred embodiments, the composition comprises coenzyme Q10 and PEG 200 to 22000, wherein the composition is in the form of a liquid, granules, a tablet or a capsule.

[0022] In preferred embodiments, the composition comprises 1 part of coenzyme Q10 and 1 to 4 parts of PEG 1000 to 22000 by weight. Preferably, the composition further comprises a filler, an expander and a lubricating excipient.

[0023] In preferred embodiments, the composition comprises 1 part of coenzyme Q10 and 1 to 10 parts of PEG 200 to 600 by weight.

[0024] In preferred embodiments, the composition is in the form of granules, tablets or capsules comprising coenzyme Q10 and poloxamer. Preferably, the composition comprises 1 part of coenzyme Q10 and 1 to 4 parts of poloxamer.

[0025] In preferred embodiments, the composition comprises coenzyme Q10, PEG 1000 to 22000 and poloxamer, wherein the composition is in the form of granules, tablets or capsules.Preferably, the composition comprises 1 part of coenzyme Q10, 1 to 3 parts of PEG 1000 to 22000, 1 to 3 parts of poloxamer by weight. Preferably, the composition further comprises a filler, an expander and a lubricating excipient.

[0026] In preferred embodiments, the composition comprises 1 part of coenzyme Q10 and 0.5 to 3 parts of docusate sodium by weight. Preferably, the composition further comprises a filler, an expander and a lubricating excipient.

[0027] In preferred embodiments, the composition comprises 1 part of coenzyme Q10, 1 to 3 parts of PEG 1000 to 22000, 1 to 3 parts of poloxamer and 0.5 to 1 parts of docusate sodium by weight and the formulation further comprises a filler, an expander and a lubricating excipient.

[0028] In preferred embodiments, the composition is in the form of a sphere comprising by weight 1 part of coenzyme Q10, 0.5 to 3 parts of HPMC of low molecular mass and 0.5 to 1 part of a core comprising sugar, microcrystalline cellulose or a mixture thereof.

[0029] In preferred embodiments, the composition comprises by weight 1 part of coenzyme Q10, 2 parts of HPMC and 1 part of a core comprising sugar, microcrystalline cellulose or a mixture thereof.

[0030] In preferred embodiments, the composition is in the form of granules or capsules comprising coenzyme Q10 and HPMC of low molecular mass, wherein the composition further comprises one or more of lactose, sugar, microcrystalline cellulose, and cross-linked povidone, or a mixture thereof.

[0031] In preferred embodiments, the composition is a liquid solution comprising coenzyme Q10 and a PEG 200 to 600. Preferably, the liquid solution is filled in a bottle or into a soft capsule. Preferably, the composition comprises 1 part of coenzyme Q10 and 1 to 10 parts of a PEG 200 to 600.

[0032] In preferred embodiments, the composition is a liquid solution comprising coenzyme Q10 and a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80.

[0033] In preferred embodiments, the composition is a liquid solution comprising coenzyme Q10, PEG 200 to 600 and a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80. Preferably, the liquid solution is filled in a bottle or into a soft capsule.

[0034] In preferred embodiments, the composition comprises by weight 1 part of coenzyme Q10, 1 to 10 parts of a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80.

[0035] In preferred embodiments, the composition comprises by weight 1 part of coenzyme Q10 and 1 to 10 parts of an organic acid selected from malic acid, maleic acid, tartaric acid, succinic acid, citric acid and ascorbic acid.

[0036] In another aspect, the present invention provides a method of producing a coenzyme Q10 composition in the form of a sphere, the method comprising the steps of: a) dissolving 1 part by weight of coenzyme Q10 in an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol, dichloromethane or trichloromethane, until the coenzyme Q10 is fully dissolved; b) dissolving 0.5 to 3 parts by weight of HPMC of low molecular mass in a solvent selected from ethanol, isopropyl alcohol or benzyl alcohol; c) mixing the solution of step a) and the solution of step b) together to form a solution comprising coenzyme Q10 and HPMC; and d) spraying the coenzyme Q10 and HPMC solution of step c) onto cores on a fluidised bed, wherein the cores comprise sugar, microcrystalline cellulose or a mixture thereof, to form a sphere containing coenzyme Q10, HPMC and a core.

[0037] In another aspect, the present invention provides a method of producing a coenzyme Q10 composition, wherein the method comprises the steps of: a) dissolving 1 part by weight of coenzyme Q10 in an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol, dichloromethane or trichloromethane until the coenzyme Q10 is fully dissolved or dispersed; b) adding 1 to 3 parts of PEG 1000 to 22000, 1 to 3 part of poloxamer or 0.5 to 1 parts of docusate sodium by weight into the solution or dispersion of step a) until the PEG, poloxamer or docusate sodium is fully dissolved or dispersed; c) placing 1 part each of lactose, microcrystalline cellulose, cross-linked povidone in a fluidised bed; d) spraying the solution or dispersion of step b) onto the fluidised bed to form a powdered mixture; e) spraying a PVP K30 solution into the fluidised bed of step d) to form granules; and f) mixing the granules of step e) with a lubricating agent, preferably magnesium stearate, and compressing the granules into a tablet or filling the granules into a capsule or granule bag.

[0038] In another aspect, the present invention provides the composition as described herein for use in providing heart nutrients to a patient with heart disease.

[0039] In another aspect, the present invention provides use of the composition as described herein in the manufacture of a medicament for treating coenzyme Q10 deficiency or a conditionrelated to coenzyme Q10 deficiency, such as heart failure, cardiomyopathy or myopathy, wherein the composition is formulated for administration of 300 mg of coenzyme Q10 to a patient daily.

[0040] In another aspect, the present invention provides a method of treating coenzyme Q10 deficiency or a condition related to coenzyme Q10 deficiency, such as heart failure, cardiomyopathy or myopathy comprising administering to a subject the composition the invention as described herein, wherein the composition is formulated for administration of 300 mg of coenzyme Q10 to a patient daily.DEFINITIONS

[0041] In order for the invention described herein to be more fully understood, the following definitions are provided for the purposes of this disclosure.

[0042] The term "comprising" is an inclusive term interpreted to mean containing, embracing, covering or including the elements listed following the term, but not excluding other unrecited elements.

[0043] The term "consisting essentially of" means the list of elements may include additional components or excipients to those listed that do not materially contribute to the working of the invention.

[0044] The term "consisting of" is an exclusive term and means consisting only of.

[0045] The term "therapeutically effective amount" or "effective amount" means an amount that, when administered to an animal for treating a disease, disorder or condition, is sufficient to produce a desired therapeutic effect (e.g., to affect treatment for that disease).

[0046] The terms “composition” and “formulation” are synonymous and are used interchangeably herein.

[0047] The term "RPM" refers to rotations per minute.

[0048] The terms “dissolution” and “dissociation” are synonymous and are used interchangeably herein.

[0049] The term "core" refers to a small sphere.

[0050] The term "PVP" refers to polyvinyl pyrrolidone.

[0051] The term "HPMC" is an abbreviation of hydroxypropyl methylcellulose (also referred to as hypromellose), which is a methyl and hydroxypropyl mixed ether.

[0052] An HPMC of low molecular mass refers to HPMC with molecular mass equal to or lower than 26,000 g / mol.

[0053] An HPMC of high molecular mass refers to HPMC with molecular mass equal or greater than 26,000 g / mol.

[0054] The term "PEG" refers to polyethylene glycol. PEG of a molecular mass of 200 to 400 g / mol may be in the form of a liquid. PEG of a molecular mass of 600 g / mol may be in the form of a semi-liquid. PEG of a molecular mass of greater than 1 ,000 g / mol may be in the form of a solid.

[0055] Polysorbate is a surfactant, examples of which include Tween® 20, Tween® 40, Tween® 60 and Tween® 80.DETAILED DESCRIPTION OF THE INVENTION

[0056] The invention will be described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications can be made while remaining within the spirit and scope of the invention.

[0057] The present invention relates to compositions comprising coenzyme Q10 and one or more water soluble excipients.

[0058] More particularly, embodiments of the present invention relate to compositions comprising coenzyme Q10 and one or more water soluble excipients such as hydroxypropyl methylcellulose (HPMC), preferably low molecular mass HPMC, PEG 1000 to 22,000, PEG 200 to 600, docusate sodium, poloxamer (e.g., Pluronic®), polysorbate such as Tween® 20, Tween® 40, Tween® 60 or Tween® 80, a filler, an expander and a lubricating excipient. The present invention further relates to methods of treating coenzyme Q10 deficiency in a subject comprising orally administering such compositions.

[0059] In preferred embodiments, the composition may be in the form of spheres, granules, capsules, tablets, soft capsules or a liquid. Preferably, the composition is an immediate-release formulation with high dissolution in an aqueous medium.

[0060] In preferred embodiments, the composition may be in the form of spheres to be administered orally. In preferred embodiments, the sphere comprises a coating on a core, wherein the coating comprises a mixture of coenzyme Q10 and HPMC, e.g., HPMC E5, over the core.

[0061] In preferred embodiments, the composition may be in the form of granules which may be filled into a capsule or a granules bag, or compressed into tablets to be administered orally. Preferably, the granule composition comprises coenzyme Q10, PEG 1000 to 22,000, poloxamer, docusate sodium, HPMC of low molecular mass equal to or lower than 26,000 g / mol, and one or more other excipients such as a filler, expander and lubricating powder.

[0062] In preferred embodiments, the composition comprises a mixture of coenzyme Q10 and a binder coating on a core, wherein the core comprises sugar, microcrystalline cellulose or a mixture thereof. Preferably, the binder is HPMC of a low molecular mass equal to or lower than 26,000 g / mol.

[0063] In another preferred embodiment, the formulation comprises coenzyme Q10, PEG of a molecular weight from 1000 to 22,000 g / mol and one or more other excipients such as a filler, expander and lubricating powder. The formulation may be in the form of granules, tablets or capsules.

[0064] In another preferred embodiment of the invention, the formulation comprises coenzyme Q10, PEG of a molecular weight from 1000 to 22,000 g / mol, poloxamer and one or more other excipients such as a filler, expander and lubricating powder, wherein the formulation is preferably in the form of granules, tablets or capsules.

[0065] In another preferred embodiment of the invention, the formulation comprises coenzyme Q10, docusate sodium, and one or more other excipients such as a filler, expander and lubricating powder, wherein the formulation is preferably in the form of granules, tablets or capsules.

[0066] In another preferred embodiment of the invention, the formulation comprises coenzyme Q10, HPMC of low molecular mass and one or more other excipients such as a filler, expander and lubricating powder, wherein the formulation is preferably in the form of granules and capsules.

[0067] In another preferred embodiment of the invention, the formulation comprises coenzyme Q10, HPMC, poloxamer, wherein the formulation is preferably in the form of granules, tablets or capsules.

[0068] In another preferred embodiment of the invention, the formulation comprises coenzyme Q10, poloxamer and PEG 1000 to 22,000, wherein the formulation is preferably in the form of granules, tablets or capsules.

[0069] In another preferred embodiment of the invention, the formulation comprises coenzyme Q10, poloxamer, PEG 1000 to 22,000 and HPMC, wherein the formulation may be in the form of granules, tablets or capsules.

[0070] In another preferred embodiment of the invention, the formulation comprises 1 part of coenzyme Q10, 1 part of poloxamer and 1 part of PEG 1000 to 22,000, wherein the formulation may be in the form of granules, tablets or capsules.

[0071] In another preferred embodiment of the invention, the formulation comprises 1 part of coenzyme Q10, 1 part of PEG 1000 to 22000, 1 part of cross-linked povidone, and 1 part ofmicrocrystalline cellulose, wherein the formulation may be in the form of granules, tablets or capsules.

[0072] In another preferred embodiment of the invention, the formulation comprises 1 part of coenzyme Q10, 2 parts of PEG 1000 to 22,000, 2 parts of cross-linked povidone, and 2 parts of microcrystalline cellulose, wherein the formulation may be in the form of granules, tablets or capsules.

[0073] In another preferred embodiment of the invention, the formulation comprises 1 part of coenzyme Q10, 10 parts of PEG 1000 to 22000, 2 parts of cross-linked povidone, and 3 parts of microcrystalline cellulose, wherein the formulation may be in the form of granules, tablets or capsules.

[0074] In another preferred embodiment of the invention, the formulation comprises 1 part of coenzyme Q10 and 1 to 10 parts of PEG 200 to 600, wherein the formulation may be in the form of a liquid or soft capsules.

[0075] In another preferred embodiment of the invention, the formulation comprises 1 part of coenzyme Q10 and 1 to 10 parts of a polysorbate such as Tween® 20, Tween® 40, Tween® 60 and Tween® 80, wherein the formulation may be in the form of a liquid or soft capsules.

[0076] In another preferred embodiment of the invention, the formulation comprises 1 part of coenzyme Q10, 1 to 2 parts of PEG 200 to 600 and 1 to 2 parts of a polysorbate such as Tween® 20, Tween® 40, Tween® 60 and Tween® 80, wherein the formulation may be in the form of a liquid or soft capsules.

[0077] In another preferred embodiment of the invention, the formulation comprises 1 part of coenzyme Q10, 1 part of poloxamer, 1 part of cross-linked povidone and 1 part of microcrystalline cellulose, wherein the formulation may be in the form of granules, tablets or capsules.

[0078] In another preferred embodiment of the invention, the formulation comprises 1 part of coenzyme Q10, 2 parts of poloxamer, 2 parts of cross-linked povidone and 2 parts of microcrystalline cellulose, wherein the formulation may be in the form of granules, tablets or capsules.

[0079] In another preferred embodiment of the invention, the formulation comprises 1 part of coenzyme Q10, 0.5 to 1 parts of docusate sodium, 1 part of cross-linked povidone and 1 part of microcrystalline cellulose, wherein the formulation may be in the form of granules, tablets or capsules.

[0080] In another preferred embodiment of the invention, the formulation comprises 1 part of coenzyme Q10, 1 part of docusate sodium, 1 part of PEG 1000 to 22000, 1 part of cross-linkedpovidone and 1 part of microcrystalline cellulose, wherein the formulation may be in the form of granules, tablets or capsules.

[0081] It was surprisingly found by the Applicant that compositions prepared according to the methods described herein can provide higher dissolution rates of coenzyme Q10 in an aqueous medium, thereby enabling a lower amount of coenzyme Q10 to be administered to provide a therapeutic effect. Accordingly, an advantage of particularly preferred embodiments of the present invention is that compositions may comprise less coenzyme Q10 per unit dosage than the dosage of currently available soft capsule compositions. This provides a benefit of reducing side effects from having high levels of coenzyme Q10 in the alimentary system, while providing the same or better efficacy. Coenzyme Q10 is currently available in the form of soft capsules. Most coenzyme Q10 formulations on the market are in the form of soft capsules containing vegetable oil and coenzyme Q10. The soft capsules of the present invention comprises water soluble excipients and do not comprise oil-based excipients, thereby helping to improve in vivo solubility.

[0082] CN 101703477 A describes the preparation of a coenzyme Q10 pellet formulation and a method of production thereof. The coenzyme Q10 pellet was prepared from coenzyme Q10 and pharmaceutical excipients, and is characterised in that the pharmaceutical excipients are excipients and binders, wherein the weight of coenzyme Q10 in the pellet preparation is from 2- 80%, the weight percentage content of the excipient is from 12-97%, and the weight percentage content of the binder is from 1-8%. The pellet preparations can be prepared as sustained-release or enteric-coated preparations as required. The coenzyme Q10 pellet was produced by (1) mixing the coenzyme Q10 and the excipient together and grinding the mixture to micronisation-grade; (2) dissolving a binder in water, a dehydrated alcohol or hydrous ethanol; and (3) using micropill-forming technology to make a micropill.

[0083] In traditional methods used by Chinese manufacturers to prepare coenzyme Q10 compositions, the degree of pulverisation of medicinal materials or extracts provides coarse powders (for oral use, having a particle diameter of 850 pm ± 70 pm, and capable of passing through 24 mesh sieves), medium powder (for oral use, having a particle diameter of 250 pm ± 9.9 pm, and capable of passing through 65 mesh sieves), fine powder (for wound trauma use, having a particle diameter of 150 pm ± 6.6 pm, and capable of passing through 100 mesh sieves), finer powder (for use in eye drops, having a particle diameter of 125 pm ± 5.8 pm, and capable of passing through 120 mesh sieves) and very fine powder (having a particle diameter of 75 pm ± 4 pm, and capable of passing through 200 mesh sieves).

[0084] The coenzyme Q10 composition of the present invention may be in the form of a sphere which comprises in its outer layer a mixture of coenzyme Q10 and hydroxypropyl methylcellulose (HPMC). The sphere may comprise a core which comprises sugar, microcrystalline cellulose or a mixture thereof. The outer layer comprising coenzyme Q10 andHPMC may be formed from numerous layers of coenzyme Q10 and HPMC. After the diameter of the sphere reaches about 1 mm, the coating process may be stopped. The resultant coated spheres may be filled into a capsule or a granule bag. The composition described herein may further comprise magnesium stearate as a lubricating agent.

[0085] The amount of dissolution of coenzyme Q10 of a composition of the invention in the form of spheres comprising 150 mg coenzyme Q10 when subjected to the conditions of 1000 mL of 0.5% Triton as the dissolution medium may be more than 60%, 70%, 80%, 90% or 95%.

[0086] An embodiment of the invention may comprise an amount of 5 mg, 10 mg, 20 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg of coenzyme Q10. Preferably, the amount of coenzyme Q10 in compositions as described herein is a reduced dose amount relative to dosage forms in the prior art.

[0087] In an embodiment, the present invention provides a composition as described herein, wherein the composition has a dissolution amount of coenzyme Q10 in a 1% Triton aqueous medium of greater than 60%, or greater than 65%, or greater than 70%, or greater than 75%, or greater than 80%, or greater than 85%, or greater than 90%, or greater than 95%.

[0088] The composition as described herein may be used to treat a subject with coenzyme Q10 deficiency, or conditions related to coenzyme Q10 deficiency, such as for example, heart failure, cardiomyopathy or myopathy.

[0089] In one embodiment, the present invention provides an oral composition which may be in the form of spheres, granules, tablets or capsules. The spheres or granules may be filled into a capsule or a granules bag, or the granules may be compressed into a tablet. The composition of the invention in the form of spheres or pellets may comprise coenzyme Q10, HPMC and a core comprising sugar or microcrystalline cellulose. The outer layer of the sphere composition may comprise coenzyme Q10 and HPMC, while the core comprises sugar, starch, lactose, mannitol, sorbitol, fructose- 1,6-diphosphate, microcrystalline cellulose, or a mixture thereof. HPMC is an abbreviation for hydroxypropyl methylcellulose (also referred to as hypromellose) which is a methyl and hydroxypropyl mixed ether having a molecular mass equal to or lower than about 26,000 g / mol. Preferably, the coenzyme Q10 sphere of the invention is an immediate-release formulation.

[0090] In one embodiment, the method of production of coenzyme Q10 sphere comprises the following steps: a) dissolving an amount of coenzyme Q10 in a ketone selected from acetone, butanone or pentanone, b) dissolving an amount of a HPMC of low molecular mass in an alcohol selected from ethanol, isopropanol, benzyl alcohol or a combination thereof,c) mixing together the coenzyme Q10 ketone solution of step a) and the HPMC alcohol solution of step b) to form a solution comprising coenzyme Q10 and HPMC which is sprayed into a fluidised bed containing cores, wherein the cores comprise one or more excipients such as starch, lactose, sugar, mannitol, sorbitol, fructose-1 ,6-diphosphate, microcrystalline cellulose, cross-linked povidone, sodium croscarmellose, or a mixture thereof, d) drying the spheres or pellets comprising coenzyme Q10 and HPMC to give resultant spheres, pellets or balls, wherein the spheres, pellets or balls are filled into a capsule or granule bag.

[0091] In one embodiment, the coenzyme Q10 spheres of the invention comprise about 1 part of coenzyme Q10 by weight, about 0.5 to 3 parts of HPMC of low molecular mass by weight, and about 0.5 to 2 parts of cores by weight, wherein the smaller the size of the sphere, the smaller the amount of core is used. The core may comprise starch, lactose, sugar, mannitol, sorbitol, fructose-1 ,6-diphosphate, microcrystalline cellulose, or a mixture thereof. Preferably, the coenzyme Q10 dissolution amount of the sphere, when stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton aqueous solution buffered at pH 4.5 with sodium acetate, is greater than 60%, 80% or 90%. For a fixed amount of coenzyme Q10 in the sphere, the greater the amount of HPMC, the higher the dissolution amount.

[0092] In one embodiment, a coenzyme Q10 composition of the invention comprises a therapeutically effective amount of coenzyme Q10 and a binder comprising HPMC of low molecular mass, and the amount of the binder may be from 1 to 3 times the weight of coenzyme Q10 of the composition. Preferably, the amount of dissolution of the coenzyme Q10 spheres, when stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton aqueous solution buffered at pH 4.5 with sodium acetate, is in the range of 60% to 95%.

[0093] In one embodiment, a coenzyme Q10 sphere of the invention comprises 1 part by weight of coenzyme Q10, 0.5 parts by weight of HPMC, and about 0.5 parts by weight of the core, wherein the core comprises sugar, microcrystalline cellulose, or a mixture thereof.Preferably, the dissolution amount of the coenzyme Q10 sphere of the invention, when stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton aqueous solution buffered at pH 4.5 with sodium acetate, is greater than 60%.

[0094] In another embodiment, a coenzyme Q10 sphere of the invention comprises 1 part by weight of coenzyme Q10, 1 part by weight of HPMC, and about 0.5 parts by weight of the core, wherein the core comprises sugar, microcrystalline cellulose, or a mixture thereof. Preferably, the amount of dissolution of the coenzyme Q10 sphere, when stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton aqueous solution buffered at pH 4.5 with sodium acetate, is greater than 80%.

[0095] In another embodiment, a coenzyme Q10 sphere of the invention comprises 1 part by weight of coenzyme Q10, 1 part by weight of HPMC, and about 1 part by weight of the core, wherein the core comprises sugar, microcrystalline cellulose, or a mixture thereof.

[0096] In another embodiment, a coenzyme Q10 sphere of the invention comprises 1 part by weight of coenzyme Q10, 1.5 parts by weight of HPMC, and about 1 part by weight of the core, wherein the core comprises sugar, microcrystalline cellulose, or a mixture thereof.

[0097] In another embodiment, a coenzyme Q10 sphere of the invention comprises 1 part by weight of coenzyme Q10, 2 parts by weight of HPMC, and about 1 part by weight of the core, wherein the core comprises sugar, microcrystalline cellulose, or a mixture thereof.

[0098] In another embodiment, a coenzyme Q10 sphere of the invention comprises 1 part by weight of coenzyme Q10, 3 parts by weight of HPMC, and about 1 part by weight of the core, wherein the core comprises sugar, microcrystalline cellulose, or a mixture thereof.

[0099] In another embodiment, a coenzyme Q10 sphere of the invention comprises 1 part by weight of coenzyme Q10, 2 parts by weight of HPMC, and about 2 parts by weight of the core, wherein the core comprises sugar, microcrystalline cellulose, or a mixture thereof.

[0100] In another embodiment, a coenzyme Q10 sphere of the invention comprises 1 part by weight of coenzyme Q10, 3 parts by weight of HPMC, and about 2 parts by weight of the core, wherein the core comprises sugar, microcrystalline cellulose, or a mixture thereof.

[0101] In another embodiment, a coenzyme Q10 composition of the invention in the form of granules comprises coenzyme Q10, HPMC of low molecular mass, a filler, an expander, starch, lactose, sugar, mannitol, sorbitol, fructose- 1 ,6-diphosphate, microcrystalline cellulose, crosslinked povidone, or a mixture thereof.

[0102] In some embodiments, the core is a small sphere of about 0.3 mm to about 1 mm diameter, and comprises sugar, starch, microcrystalline cellulose, lactose, mannitol, sorbitol, fructose-1 ,6-diphosphate, cross-linked povidone and sodium croscarmellose.

[0103] In some embodiments, the reduced dose coenzyme Q10 composition of the invention comprises a coenzyme Q10 coating on the core, wherein the composition may be filled into a capsule or granule bag.

[0104] In some embodiments, the reduced dose coenzyme Q10 composition of the invention is in the form of granules comprising coenzyme Q10 and a water soluble excipient selected from one or more of HPMC of low molecular mass, PEG 1000 to 22000, poloxamer, docusate sodium, and one or more of a filler and expander selected from microcrystalline cellulose, crosslinked povidone, sodium croscarmellose, or a mixture thereof. Preferably, the granules are filled into a capsule or granule bag, or the granules may be compressed into a tablet.

[0105] In some embodiments, the coenzyme Q10 composition of the invention comprises 1 part of coenzyme Q10, 0.5 parts of HPMC of low molecular mass,1 to 3 parts of PEG 100 to 22000, 1 to 2 parts of poloxamer, 0.5 to 1 parts of docusate sodium, 10% microcrystalline cellulose, 1 part of cross-linked povidone and, 1 part of sodium croscarmellose, or a mixture thereof, and wherein the formulation may be in the form of granules, tablets or capsules.

[0106] In some embodiments, the coenzyme Q10 composition of the invention comprises 1 part of coenzyme Q10, 1 to 2 parts of PEG 1000 to 22000, 1 part of poloxamer, 10% microcrystalline cellulose, 1 part of cross-linked povidone and 1 part of sodium croscarmellose, or a mixture thereof, and wherein the formulation may be in the form of granules, tablets or capsules.

[0107] In some embodiments, the coenzyme Q10 composition of the invention comprises 1 part of coenzyme Q10, 1 to 10 parts of PEG 1000 to 22000, 10% microcrystalline cellulose, 1 part of cross-linked povidone and 1 part of sodium croscarmellose, or a mixture thereof.

[0108] In some embodiments, the coenzyme Q10 composition of the invention comprises coenzyme Q10, poloxamer, microcrystalline cellulose, cross-linked povidone and sodium croscarmellose, or a mixture thereof.

[0109] In some embodiments, the coenzyme Q10 composition of the invention comprises coenzyme Q10 and docusate sodium.

[0110] In some embodiments, the coenzyme Q10 composition of the invention comprises coenzyme Q10 and PEG 200 to 600.

[0111] In some embodiments, the coenzyme Q10 composition of the invention comprises coenzyme Q10 and a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80, wherein the formulation may be in the form of a liquid or soft capsules.

[0112] In some embodiments, the coenzyme Q10 composition of the invention comprises coenzyme Q10 and PEG 1000 to 22000.

[0113] In some embodiments, the composition of the invention is in the form of a sphere comprising a core, the core comprising sugar, microcrystalline cellulose, or a mixture thereof, and an outer layer comprising coenzyme Q10 and HPMC of low molecular mass surrounding the core. Preferably, the sphere has a diameter of about 0.3 mm to about 2 mm, or preferably wherein the diameter is from about 0.5 mm to 1.2 mm. Preferably, the spheres may be filled into a hard capsule or a sphere bag, wherein the composition is preferably an immediate-release product.

[0114] In some embodiments, the coenzyme Q10 composition of the invention comprises 1 part of coenzyme Q10, 1 to 2 parts of poloxamer, 10% microcrystalline cellulose, 1 part of cross-linked povidone and 1 part of sodium croscarmellose, or a mixture thereof.

[0115] In some embodiments, the coenzyme Q10 composition of the invention comprises 1 part of coenzyme Q10, 0.5 to 1 parts of docusate sodium, 10% microcrystalline cellulose, 1 part of cross-linked povidone and 1 part of sodium croscarmellose, or a mixture thereof.

[0116] In some embodiments, the coenzyme Q10 composition of the invention comprises 1 part of coenzyme Q10, 0.5 to 1 parts of docusate sodium, 1 to 10 parts of PEG 1000 to 22000, 10% microcrystalline cellulose, 1 part of cross-linked povidone and 1 part of sodium croscarmellose, or a mixture thereof. In some embodiments of the sphere, the ratio of HPMC of low molecular mass to coenzyme Q10 is in the range from 0.5:1 to 3:1 by weight. Preferably, the ratio is from 1 :1 to 2:1 by weight.

[0117] Hydroxypropyl methylcellulose (HPMC) is a water-soluble methylcellulose ether. In preferred embodiments of the invention, the HPMC has a low molecular mass. Preferably, HMPC is used as a binder. HPMC polymers are available in various viscosity grades ranging from 4,000-100,000 mPas. The viscosity of the polymer affects the diffusion pathway. High molecular mass HPMC may be employed as a matrix for controlling the release of both hydrophilic and hydrophobic drugs and is a critical excipient of sustained-release formulations. In slow-release tablets, the HPMC may act as a retarding agent. In preferred embodiments of the invention, the low molecular mass HPMC acts as a binder only.

[0118] In preferred embodiments, a coenzyme Q10 composition of the invention is produced by following method: a) 1 part of coenzyme Q10 powder by weight is placed in a tank and mixed with about 6 parts by weight of a ketone selected from acetone, butanone or pentanone until the powder is fully dissolved; b) 0.5 to 3 parts by weight of HPMC of low molecular mass is placed in the tank with about 1 to 18 parts by weight of an alcohol selected from ethanol, isopropanol or benzyl alcohol until the HPMC is fully dissolved; c) 1 part by weight of cores having a diameter of 0.4 mm to 1.0 mm are placed in a fluidised bed, wherein the cores comprise sugar, microcrystalline cellulose, or a mixture thereof; d) the solutions of step a) and b) are mixed together; e) the solution of step d) is sprayed onto the fluidised bed, wherein the solution adheres and dries on the surface of the cores, coating the cores and increasing their size; and f) the resultant spheres obtained from step e) are filled into a capsule or granule bag.

[0119] In other embodiments, the coenzyme Q10 composition of the invention may be produced by the following method: a) 1 part by weight of coenzyme Q10 powder is placed in a tank with about 3 to 6 parts by weight of a ketone selected from acetone, butanone or pentanone until the powder is fully dissolved; b) 0.5 to 3 parts by weight of HPMC of low molecular mass is dissolved or dispersed in 1 to 18 parts by weight of water; c) the aqueous HPMC solution or mixture of step b) is mixed with the coenzyme Q10 ketone solution of step a) to form a suspension; d) 1 part by weight of cores having a diameter of 0.4 mm to 1.0 mm is placed in a fluidised bed, wherein the cores comprise sugar, microcrystalline cellulose, or a mixture thereof; e) the resultant suspension of step c) is sprayed onto the fluidised bed, wherein the suspension adheres and dries on the surface of the cores, coating the cores and increasing their size; f) the resultant spheres obtained from step e) are filled into a capsule or granule bag.

[0120] In another embodiment, the coenzyme Q10 composition of the invention may be in the form of granules and may be produced according to the following method: a) 1 part by weight of coenzyme Q10 powder is placed in a tank with about 6 parts by weight of a ketone selected from acetone, butanone or pentanone until the powder is fully dissolved; b) 0.5 to 3 parts by weight of HPMC of low molecular mass is dissolved in about 3 to 18 parts by weight of water; c) 1 to 3 parts by weight of a filler and expander is placed in a fluidised bed, wherein the filler and expander comprises sugar, microcrystalline cellulose, lactose, crosslinked povidone, or a mixture thereof; d) a mixture of the solutions from a) and b) is sprayed onto the fluidised bed; wherein the mixture adheres and dries with the filler and expander, forming granules which are allowed to increase in size until the granules are about 24 mesh; e) an aqueous solution of PVPK30 is sprayed onto the fluidised bed, increasing the size of the granules; and f) the granules of step e) are mixed with magnesium stearate, and then filled into a capsule, granule bag or compressed into a tablet.

[0121] In another embodiment, the coenzyme Q10 composition of the invention may be produced according to the following method:a) 1 part by weight of coenzyme Q10 powder is placed in a tank with about 6 parts by weight of a ketone selected from acetone, butanone or pentanone until the powder is fully dissolved; b) 1 to 3 parts by weight of PEG 1000 to 22000 is dissolved in the solution of step a); c) 1 to 3 parts by weight of a filler and expander is placed in a fluidised bed, wherein the filler and expander comprises microcrystalline cellulose, lactose, cross-linked povidone, or a mixture thereof; d) the solution of step b) is sprayed onto the fluidised bed; wherein the mixture adheres and dries with the filler and expander, forming granules which are allowed to increase in size until the granules are about 24 mesh; e) an aqueous solution of PVPK30 is sprayed onto the fluidised bed, increasing the size of the granules; and f) the granules of step e) are mixed with magnesium stearate, and then filled into a capsule, granule bag or compressed into a tablet.

[0122] In one embodiment of the invention, the ratio of HPMC of low molecular mass to coenzyme Q10 is 0.5:1 by weight. In another embodiment, the ratio of HPMC to coenzyme Q10 is 1 :1 by weight. In another embodiment, the ratio of HPMC to coenzyme Q10 is 2:1 by weight. In another embodiment, the ratio of HPMC to coenzyme Q10 is 3:1 by weight. Preferably, the ratio of HPMC of low molecular mass to coenzyme Q10 is from 1:1 to 2:1 by weight.

[0123] Preferably, after the coenzyme Q10 composition of the invention in the form of capsules comprising spheres is disintegrated in aqueous solution, the dissolution of coenzyme Q10 is much higher than the dissolution of prior art coenzyme Q10 soft capsules of the same strength. Preferably, this increases the absorption of coenzyme Q10 in the alimentary system and reduces side effects from elevated coenzyme Q10 levels compared with the prior art soft capsules.

[0124] Coenzyme Q10 may have a variety of adverse reactions which are infrequent and generally mild. These may include decreased appetite, diarrhea, dizziness, dyspepsia, nausea and vomiting. However, decreasing the amount of coenzyme Q10 in the alimentary system may reduce the frequency and / or severity of these side effects.

[0125] Coenzyme Q10 as a food supplement or drug is available in single capsule doses of 30, 60, 100, 200, 300, 400 and 600 mg. Generally, the dose required for attaining a therapeutic plasma concentration of >2.5 pg / mL is 200 mg administered twice daily with a meal. In subjects with heart disease, daily doses of 100 to 400 mg have been used, while in neurodegenerative diseases, maximum doses of 3,000 mg have been used. Coenzyme Q10 may also reduce statin-associated muscle symptoms and death rates from heart failure.

[0126] The coenzyme Q10 composition of the invention may comprise different amounts of coenzyme Q10 in the range of from 20 mg to 600 mg. Preferably, the composition may be in the form of spheres, granules, tablets, capsules, a liquid or soft capsules.

[0127] In another embodiment, the composition of the invention comprises 1 part by weight of coenzyme Q10, 0.5 to 3 parts by weight of HPMC of low molecular mass, and 0.5 to 1 parts by weight of a core, the core comprising sugar, microcrystalline cellulose, or a mixture thereof.

[0128] In another embodiment, the composition of the invention in the form of spheres comprises 20 to 150 mg of coenzyme Q10, 20 to 300 mg of HPMC of low molecular mass, and 20 to 150 mg of a sugar core. Preferably, the coenzyme Q10 dissolution amount of the spheres, when stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton aqueous solution buffered at pH4.5 with sodium acetate, is about 92.5%. In some embodiments, the spheres may be filled into a capsule or a pellet bag.

[0129] In another embodiment, the composition of the invention is in the form of a sphere comprising 150 mg of coenzyme Q10, 150 mg of HPMC of low molecular mass, and 150 mg of a core comprising sugar, microcrystalline cellulose or a mixture thereof.

[0130] In another embodiment, the composition of the invention is in the form of a sphere, comprising 120 mg of coenzyme Q10, 240 mg of HPMC of low molecular mass, and 100 mg of a sugar core. Preferably, the amount of dissolution of coenzyme Q10 of the spheres in 1000 mL of 0.5% Triton aqueous solution of pH 4.5 when stirred at 75 RPM for 2 hours is greater than 80%.

[0131] In another embodiment, the composition of the invention is in the form of a sphere comprising 100 mg of coenzyme Q10, 200 mg of HPMC of low molecular mass and 100 mg of a core comprising a mixture of sugar and microcrystalline cellulose. Preferably, the amount of dissolution of coenzyme Q10 of the spheres in 1000 mL of 0.5% Triton aqueous solution of pH4.5 when stirred at 75 RPM for 2 hours is greater than 80%.

[0132] In another embodiment, the composition of the invention is in the form of a sphere comprising 100 mg of coenzyme Q10, 150 mg of HPMC of low molecular mass and 100 mg of a core comprising a mixture of sugar and microcrystalline cellulose. Preferably, the amount of dissolution of coenzyme Q10 of the spheres in 1000 mL of 0.5% Triton aqueous solution of pH4.5 when stirred at 75 RPM for 2 hours is greater than 80%.

[0133] In another embodiment, the composition of the invention is in the form of a sphere comprising 75 mg of coenzyme Q10, 75 to 150 mg of HPMC of low molecular mass and 50 to 100 mg of a core comprising a mixture of sugar and microcrystalline cellulose.

[0134] In another embodiment, the composition of the invention is in the form of a sphere comprising 45 mg of coenzyme Q10, 45 to 90 mg of HPMC of low molecular mass and 45 to 90 mg of a core comprising a mixture of sugar and microcrystalline cellulose.

[0135] In another embodiment, the composition of the invention is in the form of a tablet comprising 45 mg of coenzyme Q10, 45 to 135 mg of PEG 1000 to 22000 and 45 to 90 mg of poloxamer and cross-linked povidone, cross-linked sodium carboxymethyl cellulose, lactose and microcrystalline cellulose.

[0136] In another embodiment, the composition of the invention is in the form of a tablet comprising 100 mg of coenzyme Q10, 100 to 300 mg of PEG 1000 to 22000 and 100 to 200 mg of poloxamer. Preferably, the formulation further comprises cross-linked povidone, cross-linked sodium carboxymethyl cellulose, lactose and microcrystalline cellulose.

[0137] In one embodiment, a method of producing the coenzyme Q10 composition of the invention comprises the following steps: a) 1 part of coenzyme Q10 by weight is mixed with about 2 parts of acetone by weight until the coenzyme Q10 is fully dissolved; b) 0.5 to 3 parts by weight of HPMC of low molecular mass is mixed with 1.5 to 18 parts by weight of ethanol; c) the coenzyme Q10 acetone solution of step a) and the HPMC ethanol solution of step b) are mixed together; d) 1 part by weight of cores comprising sugar, microcrystalline cellulose, or a mixture thereof is placed in a fluidised bed; e) the solution of step c) is sprayed onto the fluidised bed; wherein the solution adheres and dries on the surface of the cores, coating the cores and increasing their size to give spheres; and f) the resultant spheres are mixed with magnesium stearate, and are filled into a capsule or granule bag.

[0138] In an embodiment, the present invention provides a Q10 composition as described herein for use in providing heart nutrients to a patient with heart disease.

[0139] In an embodiment, the present invention provides a method of treating coenzyme Q10 deficiency or conditions related to coenzyme Q10 deficiency, such as heart failure, cardiomyopathy or myopathy, the method comprising administering to a patient the decomposition as described herein, wherein less than 300 mg of coenzyme Q10 is administered to the patient once daily.

[0140] In an embodiment, the present invention provides use of the Q10 composition as described herein for treating coenzyme Q10 deficiency or conditions related to coenzyme Q10deficiency, such as heart failure, cardiomyopathy or myopathy, wherein the composition is formulated for administration of 300 mg of coenzyme Q10 to a patient once daily.

[0141] In some embodiments, the composition of the invention is used to treat subjects with coenzyme Q10 deficiency, heart failure, myopathy or cardiomyopathy in a dosage from 5 mg to 600 mg per day. In some embodiments, the daily dosage is 600 mg of coenzyme Q10 per day. In some embodiments, the daily dosage is 500 mg of coenzyme Q10 per day. In some embodiments, the daily dosage is 400 mg of coenzyme Q10 per day. In some embodiments, the daily dosage is 300 mg of coenzyme Q10 per day. In some embodiments, the daily dosage is 200 mg of coenzyme Q10 per day. In some embodiments, the daily dosage is 150 mg of coenzyme Q10 per day. In some embodiments, the daily dosage is 100 mg of coenzyme Q10 per day. In some embodiments, the daily dosage is 50 mg of coenzyme Q10 per day. In some embodiments, the daily dosage is 10 mg of coenzyme Q10 per day. In some embodiments, the daily dosage is 5 mg of coenzyme Q10 per day.

[0142] In some embodiments, the amount of coenzyme Q10 in the composition of the invention is from 5 mg to 150 per capsule and is used to treat subjects with coenzyme Q10 deficiency, heart failure, myopathy and cardiomyopathy in a dosage from 5 mg to 600 mg per day. In some embodiments, the amount of coenzyme Q10 is 5 mg per capsule. In some embodiments, the amount of coenzyme Q10 is 10 mg per capsule. In some embodiments, the amount of coenzyme Q10 is 20 mg per capsule. In some embodiments, the amount of coenzyme Q10 is 50 mg per capsule. In some embodiments, the amount of coenzyme Q10 is 100 mg per capsule. In some embodiments, the amount of coenzyme Q10 is 120 mg per capsule. In some embodiments, the amount of coenzyme Q10 is 150 mg per capsule.

[0143] Preferably, the capsules comprise spheres comprising a coenzyme Q10 and HPMC coating on the core, wherein the core comprises sugar and microcrystalline cellulose, or a mixture thereof.

[0144] Coenzyme Q10 is a water-insoluble chemical and its dissolution is low in an aqueous medium. When testing the amount of dissolution of coenzyme Q10 of the coenzyme Q10 soft capsules and API, the amount of dissolution of coenzyme Q10 is about the same in both coenzyme Q10 API, or coenzyme Q10.

[0145] In some embodiments, the composition of the invention is in the form of a sphere comprising water-insoluble coenzyme Q10 and a water-soluble HPMC of low molecular mass, both of which are coated on the outside of a core comprising sugar, microcrystalline cellulose or a mixture thereof. This composition may be in the form of spheres or a hard capsule comprising said spheres. Preferably, the spheres or hard capsules comprising said spheres have a higher coenzyme Q10 dissolution amount in an aqueous medium than the coenzyme Q10 raw material or coenzyme Q10 soft capsules, when subject to the same dissolution conditions.

[0146] In another embodiment, the composition of the invention is in the form of granules, a tablet or a capsule. The granules may comprise water-insoluble coenzyme Q10 and a water- soluble HPMC of low molecular mass, wherein the granules further comprise excipients such as microcrystalline cellulose, lactose and cross-linked povidone. The granules may be compressed into a tablet or filled into a hard capsule. Preferably, the granules or tablets of the invention have a higher coenzyme Q10 dissolution amount in an aqueous medium than the coenzyme Q10 raw material or coenzyme Q10 soft capsules, when subjected to the same dissolution conditions.

[0147] In another embodiment, the composition of the invention is in the form of granules, a tablet or a capsule. The granules may comprise coenzyme Q10, PEG 1000 to 22000, poloxamer and docusate sodium, HPMC, wherein the granules may further comprise one or more excipients such as microcrystalline cellulose, lactose and cross-linked povidone and crosslinked sodium carboxymethyl cellulose. The granules may be compressed into a tablet or filled into a hard capsule. Preferably, the granules or tablets of the invention have a higher coenzyme Q10 dissolution amount in an aqueous medium than the coenzyme Q10 raw material or coenzyme Q10 soft capsules, when subjected to the same dissolution conditions.

[0148] The present invention broadly relates to a convenient drug delivery system, and methods of producing the drug delivery system, preferably using common excipients via a simple method and at low cost.

[0149] In one embodiment, the method of producing the coenzyme Q10 composition in the form of spheres comprises the following steps: a) 1 part by weight of coenzyme Q10 is mixed in an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropanol, benzyl alcohol, dichloromethane or trichloromethane until the coenzyme Q10 is fully dissolved; b) 0.5 to 3 parts by weight of HPMC of low molecular mass is dissolved in 1.5 to 9 parts by weight of an alcohol; c) the coenzyme Q10 solution of step a) and the HPMC solution of step b) are mixed together to form a solution; d) 1 part by weight of cores comprising sugar, microcrystalline cellulose, or a mixture thereof is placed in a fluidised bed; e) the solution of step c) comprising coenzyme Q10 and HPMC is sprayed onto the fluidised bed containing the cores and coating the cores and increasing their size until a desired size of resultant spheres is obtained; and f) the spheres of step e) are mixed with magnesium stearate; and the resultant spheres are filled into a capsule or pellet bag.

[0150] In another embodiment, the method of producing a composition of the invention in the form of granules comprises the following steps:a) 1 part by weight of coenzyme Q10 is mixed into an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol, dichloromethane or trichloromethane until the coenzyme Q10 is fully dissolved; b) 1 to 3 parts by weight of HPMC of low molecular mass is dissolved in 3 to 18 parts by weight of an alcohol selected from ethanol, benzyl alcohol or isopropyl alcohol; c) the solutions of steps a) and b) are mixed together to form a solution comprising HPMC and coenzyme Q10; d) a filler and expander comprising 1 part by weight of microcrystalline cellulose, 1 part by weight of lactose and 1 part by weight of cross-linked povidone is placed in a fluidised bed; e) the solution of step c) comprising coenzyme Q10 and HPMC is sprayed onto the fluidised bed to form a powder mixture with the microcrystalline cellulose, lactose and cross-linked povidone; f) the powder mixture of step e) is sprayed with PVPK30 to form granules, which are mixed with magnesium stearate; and g) the resultant granules of step f) are compressed into a tablet, or filled into a capsule or granule bag.

[0151] In another embodiment, the method of producing a composition of the invention in the form of granules comprises the following steps: a) 1 part by weight of coenzyme Q10 is mixed into an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol, dichloromethane or trichloromethane until the coenzyme Q10 is fully dissolved; b) 1 to 3 parts by weight of HPMC of low molecular mass is mixed with 3 to 18 parts by weight of water to form a suspension; c) the coenzyme Q10 solution of step a) and the HPMC suspension of step b) are mixed together to form a suspension comprising coenzyme Q10 and HPMC; d) 1 part by weight of cores comprising sugar, microcrystalline cellulose or a mixture thereof is placed in a fluidised bed; e) the suspension of step c) comprising coenzyme Q10 and HPMC is sprayed onto the fluidised bed; and f) the resultant sphere of step e) is filled into a capsule or granule bag.

[0152] The solid composition of the invention can be produced by wet granulator.

[0153] Preferably, the higher coenzyme Q10 dissolution amount of the present invention compared with prior art coenzyme Q10 soft capsules or tablets may reduce the amount of coenzyme Q10 needed to be administered to treat heart disease, which will in turn reduce the alimentary side effects of excessive coenzyme Q10 in the gastrointestinal system. Preferably, the weight ratio of HPMC of low molecular mass to coenzyme Q10 in compositions of the invention is in the range of from 0.5:1 to 3:1, or preferably from 1 :1 to 2:1.

[0154] In some embodiments, the coenzyme Q10 composition of the invention comprises5 mg to 300 mg of coenzyme Q10, wherein the formulation is in the form of spheres, or a capsule or a spheres bag comprising said spheres. Preferably, the amount of dissolution of coenzyme Q10 of the composition when stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton aqueous solution of pH 4.5 is greater than 80%.

[0155] In another embodiment, the coenzyme Q10 composition of the invention is in the form of a sphere which comprises 150 mg of coenzyme Q10, 150 mg to 300 mg of HPMC, and 100 to 150 mg of a core, wherein the core comprises sugar, microcrystalline cellulose, or a mixture thereof. Preferably, the composition is in the form of spheres, or a capsule comprising said spheres. Preferably, the amount of dissolution of the coenzyme Q10 composition is greater than 80% when stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton aqueous solution at pH 4.5.

[0156] In another embodiment, the coenzyme Q10 composition of the invention comprises 120 mg of coenzyme Q10 and 120 mg to 240 mg of HPMC, wherein the composition is in the form of spheres or a capsule comprising said spheres. Preferably, the amount of dissolution of coenzyme Q10 of the composition is greater than 80% when stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton aqueous solution at pH 4.5.

[0157] In another embodiment, the coenzyme Q10 composition of the invention comprises 50 mg of coenzyme Q10 and 50 mg to 150 mg of HPMC, wherein the composition is in the form of spheres, or a capsule comprising said spheres. Preferably, the amount of dissolution of coenzyme Q10 of the composition is greater than 80% when stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton aqueous solution at pH 4.5.

[0158] In another embodiment, the coenzyme Q10 composition of the invention comprises 30 mg of coenzyme Q10 and 60 mg to 90 mg of HPMC, wherein the composition is in the form of spheres or a capsule comprising said spheres. Preferably, the amount of dissolution of coenzyme Q10 of the composition is greater than 80% when stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton aqueous solution at pH 4.5.

[0159] In another embodiment, the coenzyme Q10 composition of the invention comprises 30 mg of coenzyme Q10, 30 mg to 90 mg of PEG 1000 to 22000, and 30 to 60 mg of poloxamer, wherein the composition is in the form of granules, capsule or tablets.

[0160] In another embodiment, the coenzyme Q10 composition of the invention comprises 30 mg to 150 mg of coenzyme Q10, 30 mg to 450 mg of PEG 1000 to 22000, and 30 to 450 mg of poloxamer, wherein the composition is in the form of capsule or tablets.

[0161] In another embodiment, the coenzyme Q10 composition of the invention comprises 200 mg of coenzyme Q10, 600 mg of PEG 1000 to 22000, 200 mg of poloxamer, 100 mg ofmicrocrystalline cellulose, and 200 mg of cross-linked povidone, wherein the composition is in the form of granules or tablets.

[0162] In another embodiment, the coenzyme Q10 composition of the invention comprises 150 mg of coenzyme Q10, 300 mg of PEG 1000 to 22000, 300 mg of poloxamer, 100 mg of microcrystalline cellulose, and 150 mg cross-linked povidone, wherein the composition is in the form of granules or tablets.

[0163] In another embodiment, the coenzyme Q10 composition of the invention comprises 30 mg to 150 mg of coenzyme Q10, 30 mg to 300 mg of PEG 1000 to 22000, 30 to 300 mg of poloxamer, 30 to 75 mg of docusate sodium, 30 to 75 mg of HPMC and 30 to 300 mg of an organic acid selected from malic acid, maleic acid, tartaric acid, succinic acid, citric acid, or ascorbic acid, wherein the composition is in the form of granules, capsules or tablets.

[0164] In another embodiment, the coenzyme Q10 composition of the invention comprises 30 mg to 150 mg of coenzyme Q10, 30 mg to 300 mg of PEG 1000 to 22000, 30 to 300 mg of poloxamer, 30 to 150 mg of HPMC and 30 to 300 mg of an organic acid selected from malic acid, maleic acid, tartaric acid, succinic acid, citric acid or ascorbic acid, wherein the composition is in the form of granules, capsules or tablets.

[0165] In another embodiment, the coenzyme Q10 composition of the invention comprises 1 part of coenzyme Q10 and 1 to 3 parts of PEG 1000 to 22000, and 1-3 parts of poloxamer wherein the composition is in the form of capsules or tablets.

[0166] In another embodiment, the coenzyme Q10 composition of the invention comprises 30 mg to 150 mg of coenzyme Q10, 30 mg to 150 mg of PEG 1000 to 22000, 30 to 150 mg of poloxamer, 30 to 75 mg of docusate sodium and 30 to 150 mg of an organic acid selected from malic acid, maleic acid, tartaric acid, succinic acid, citric acid or ascorbic acid, wherein the composition is in the form of granules, capsules or tablets.

[0167] In another embodiment, the coenzyme Q10 composition of the invention comprises 1 part of coenzyme Q10, 1 to 3 parts of HPMC of low molecular mass, 1 to 3 parts of PEG 1000 to 22000, 1 to 3 parts of poloxamer, 1 part of docusate sodium and 1 to 3 parts of an organic acid selected from malic acid, maleic acid, tartaric acid, succinic acid, citric acid or ascorbic acid, or a mixture thereof; wherein the composition is in the form of granules, capsules or tablets.

[0168] In another embodiment, the coenzyme Q10 composition of the invention comprises 30 mg to 150 mg of coenzyme Q10, 30 mg to 450 mg of PEG 1000 to 22000, 30 to 450 mg of poloxamer, 30 to 150 mg of docusate sodium, 30 to 150 mg of HPMC and 30 to 450 mg of an organic acid selected from malic acid, maleic acid, tartaric acid, succinic acid, citric acid or ascorbic acid, wherein the composition is in the form of granules, capsules or tablets.

[0169] The composition of the invention may be a liquid solution or a solid dosage form comprising coenzyme Q10, a water soluble excipient such as HPMC, PEG, docusate sodium, poloxamer or Pluronics, and polysorbate, wherein the composition has a high amount of dissolution of coenzyme Q10 of greater than 60% in an aqueous medium, wherein the composition may be used for treating coenzyme Q10 deficiency in a subject. The composition may have a high amount of dissolution of coenzyme Q10 in an aqueous medium of 0.5% Triton of pH 4.5 of greater than 70%, 80%, or 90%

[0170] The liquid composition of the invention may be in the form of soft capsules comprising coenzyme Q10, PEG 200 to 600 and a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80, or a mixture thereof. The liquid solution may be filled into a bottle for oral use.

[0171] The composition of the invention may be in the form of spheres comprising coenzyme Q10, a core comprising one or more excipients, and a binder comprising HPMC of low molecular mass. Preferably, the molecular mass of HPMC is equal to or lower than 26,000 g / mol.

[0172] The composition of the invention may be in the form of spheres comprising a mixture of HPMC and coenzyme Q10 coating on the surface of a core, wherein the core comprises sugar, microcrystalline cellulose or a mixture thereof.

[0173] The core of spheres of the composition may comprise one or more of sugar, microcrystalline cellulose, lactose, starch, mannitol, sorbitol, fructose-1 ,6-diphosphate, and cross-linked povidone, or a mixture thereof.

[0174] The composition of the invention may comprise coenzyme Q10, PEG 1000 to 22000, poloxamer, and polysorbate, wherein the composition may be in the form of granules, tablets, capsules or a liquid. The composition of the invention may comprise: a) 1 part of coenzyme Q10, 10 parts of PEG 1000 to 22000, wherein the composition may be in the form of granules, tablets or capsules further comprising a filler, an expander and a lubricant; b) 1 part of coenzyme Q10, 2 parts of PEG 1000 to 22000, wherein the composition may be in the form of granules, tablets or capsules further comprising a filler, an expander and a lubricant; c) 1 part of coenzyme Q10, 3 parts of PEG 1000 to 22000, wherein the composition may be in the form of granules, tablets or capsules further comprising a filler, an expander and a lubricant; d) 1 part of coenzyme Q10, 1 part of poloxamer, and wherein the composition further comprises a filler, an expander and a lubricant;e) 1 part of coenzyme Q10, 2 parts of poloxamer, and wherein the composition further comprises a filler, an expander and a lubricant; f) 1 part of coenzyme Q10, 3 parts of poloxamer, and wherein the composition further comprises a filler, an expander and a lubricant; g) 1 part of coenzyme Q10, 1 part of PEG 200 to 600, wherein the composition may be in the form of a liquid which can be filled into a soft capsule; h) 1 part of coenzyme Q10, 2 parts of PEG 200 to 600, wherein the composition may be in the form of a liquid which can be filled into a soft capsule; i) 1 part of coenzyme Q10, 10 parts of PEG 200 to 600, wherein the composition may be in the form of a liquid which can be filled into a soft capsule; j) 1 part of coenzyme Q10, 1 part of a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80, or a mixture whereof, wherein the composition may be in the form of a liquid which can be filled into a soft capsule; k) 1 part of coenzyme Q10, 2 parts of a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80, or a mixture thereof, wherein the composition may be in the form of a liquid which can be filled into a soft capsule; l) 1 part of coenzyme Q10, 10 parts of a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80, or a mixture thereof, wherein the composition may be in the form of a liquid which can be filled into a soft capsule; m) 1 part of coenzyme Q10, 0.5 to 1 parts of docusate sodium by weight, wherein the composition is in the form of granules, tablets or capsules further comprising a filler, an expander and a lubricant; n) 1 part of coenzyme Q10, 1 to 3 parts of PEG 1000 to 22000, 1 to 3 parts of poloxamer and 0.5 to 1 parts of docusate sodium by weight, wherein the composition further comprises a filler, an expander and a lubricant; o) 1 part of coenzyme Q10, 1 to 3 parts of PEG 1000 to 22000, 0.5 to 1 parts of docusate sodium, 0.5 to 1 parts of HPMC, wherein the composition may further comprises a filler, an expander and a lubricating excipient, wherein the composition is preferably in the form of granules, tablets or capsules; or p) 1 part of coenzyme Q10, 1 to 3 parts of PEG 1000 to 22000, 1 to 3 parts of poloxamer and 0.5 to 1 parts of docusate sodium by weight, wherein the composition further comprises a filler, an expander and a lubricating excipient.

[0175] The composition of the invention may be in the form of a sphere comprising by weight: a) 1 part of coenzyme Q10, 0.5 to 3 parts of HPMC of low molecular mass and 1 part of a core comprising sugar, microcrystalline cellulose or a mixture thereof; b) 1 part of coenzyme Q10, 1 parts of HPMC of low molecular mass and 1 part of a core comprising sugar, microcrystalline cellulose or a mixture thereof;c) 1 part of coenzyme Q10, 2 parts of HPMC of low molecular mass and 1 part of a core comprising sugar, microcrystalline cellulose or a mixture thereof; or d) 1 part of coenzyme Q10, 3 parts of HPMC of low molecular mass and 1 part of a core comprising sugar, microcrystalline cellulose or a mixture thereof.

[0176] In a preferred embodiment, the composition of the invention may be in the form of granules or capsules comprising coenzyme Q10 and HPMC of low molecular mass, wherein the composition further comprises lactose, microcrystalline cellulose, cross-linked povidone, or a mixture thereof.

[0177] In a preferred embodiment, the composition of the invention comprises coenzyme Q10 and PEG 200 to 600, preferably wherein the composition is in the form of a liquid or soft capsules.

[0178] In a preferred embodiment, the composition of the invention may be a liquid solution comprising coenzyme Q10, PEG 200 to 600 and a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80, or a mixture thereof, wherein the composition may be in the form of a soft capsule.

[0179] In a preferred embodiment, the composition of the invention may be a liquid solution comprising 1 part of coenzyme Q10, 1 part of PEG 200 to 600 and 1 part of a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80, or a mixture thereof, wherein the composition may be in the form of a soft capsule.

[0180] In a preferred embodiment, the composition of the invention may be a liquid solution comprising 1 part of coenzyme Q10, 2 parts of PEG 200 to 600 and 1 to 2 parts of a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80, or a mixture thereof, wherein the liquid may be filled into a soft capsule or a bottle.

[0181] In a preferred embodiment, the composition of the invention comprises by weight 1 part of coenzyme Q10, 1 to 10 parts of a polysorbate selected from Tween® 20, Tween® 40, Tween® 60 and Tween® 80, wherein the composition may be in the form of a soft capsule.

[0182] In an embodiment, a method of producing a coenzyme Q10 composition in the form of spheres comprises the steps of: a) dissolving 1 part by weight of coenzyme Q10 in an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol, dichloromethane or trichloromethane, until the coenzyme Q10 is fully dissolved; b) dissolving 1 to 3 parts by weight of HPMC of low molecular mass in a solvent selected from ethanol, isopropyl alcohol or benzyl alcohol; c) mixing the solution of step a) and the solution of step b) together to form a solution comprising coenzyme Q10 and HPMC; andd) spraying the coenzyme Q1O and HPMC solution of step c) onto cores on a fluidised bed, wherein the cores comprise sugar, microcrystalline cellulose or a mixture thereof, to form spheres.

[0183] In an embodiment, a method of producing a coenzyme Q10 composition comprises the steps of: a) dissolving 1 part by weight of coenzyme Q10 in an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol, dichloromethane or trichloromethane; b) adding 1 to 3 parts of PEG 1000 to 22000, 1 to 3 parts of poloxamer or 0.5 parts of docusate sodium by weight into the solution of step a) until the PEG, poloxamer or docusate sodium is fully dissolved or dispersed; c) 1 part each of lactose, microcrystalline cellulose, and cross-linked povidone, are placed in the fluidised bed; d) spraying the mixture of step b) comprising coenzyme Q10 onto the cores on a fluidised bed to form a powder mixture; e) spraying a PVP K30 solution into the fluidised bed of step d) to form granules; and f) mixing the granules of step e) with a lubricating agent such as magnesium stearate, and compressing into a tablet or filling into a capsule or granule bag.

[0184] The composition of invention may be used to provide heart nutrients to a patient with heart disease.

[0185] In another embodiment, the invention provides use of the composition of the invention in the manufacture of a medicament for treating coenzyme Q10 deficiency or a condition related to coenzyme Q10 deficiency, such as heart failure, cardiomyopathy or myopathy, wherein the composition is formulated for the administration of 300 mg of coenzyme Q10 to a patient once daily.GENERAL METHODS FOR MANUFACTURE

[0186] The following embodiments illustrate the method of production of a composition comprising coenzyme Q10 in accordance with the present invention.

[0187] In an embodiment, the composition of the invention comprises coenzyme Q10, HPMC of low molecular mass, and a core comprising sugar, microcrystalline cellulose, or a mixture thereof. The coenzyme Q10 and HPMC are mixed together as a layer of coating on the surface of the core. Preferably, the weight ratio of HPMC to coenzyme Q10 is in the range from about 0.5:1 to 3:1.

[0188] Preferably, coenzyme Q10 compositions in the form of spheres or a capsule comprising spheres according to the invention have a higher coenzyme Q10 dissolution amountin an aqueous medium or in the alimentary system, increasing absorption in a human body if ingested compared with coenzyme Q10 soft capsules of the prior art.

[0189] In an embodiment, the coenzyme Q10 composition of the invention is in the form of granules comprising coenzyme Q10, PEG 1000 to 22000, poloxamer and HPMC of low molecular mass, and a filler and expander comprising microcrystalline cellulose, lactose and cross-linked povidone and crosslinked sodium carboxymethyl cellulose. A solution comprising HPMC and coenzyme Q10 is mixed with microcrystalline cellulose, lactose and cross-linked povidone in a fluidised bed. The composition of the invention may be in the form of granules, tablets or capsules comprising said granules.

[0190] The formulation of the invention may be prepared in a variety of ways known to those skilled in the art.General method for manufacturing spheres

[0191] The following embodiments illustrate methods for manufacturing the composition of the invention including in the form of spheres and capsules in accordance with the present invention.

[0192] In one embodiment, a coenzyme Q10 composition of the invention in the form of spheres is produced using the following method: a) 1 part by weight of coenzyme Q10 raw material is dissolved in 2 to 6 parts by weight of an organic solvent, wherein the organic solvent is selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol, dichloromethane and trichloromethane; b) 1 to 3 parts by weight of HPMC is dissolved in 2 to 18 parts by weight of an alcohol selected from ethanol, benzyl alcohol, and isopropyl alcohol, or dispersed in a large amount of water; c) 1 part by weight of cores comprising sugar, microcrystalline cellulose, or a mixture thereof are placed in a fluidised bed; d) the solution of step a) and the solution or suspension of step b) are mixed together and sprayed onto the fluidised bed comprising the cores; e) the resultant spheres of step d) are mixed with magnesium stearate; and f) the resultant spheres of step e) are filled into a capsule or a sphere bag.General method for manufacturing granules with HPMC

[0193] The following embodiments illustrate methods for manufacturing the composition of the invention including in the form of granules, tablets and capsules in accordance with the present invention.a) 1 part by weight of coenzyme Q10 raw material is dissolved in 2 to 6 parts by weight of an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol dichloromethane or trichloromethane until fully dissolved; b) 1 to 3 parts by weight of HPMC is dissolved in 2 to 18 parts by weight of an alcohol selected from ethanol, isopropanol or benzyl alcohol until fully dissolved; c) the coenzyme Q10 solution of step a) and the HPMC solution of step b) are mixed together; d) 1 part by weight of crosslinked sodium carboxymethyl cellulose, 1 part by weight of crosslinked povidone and 1 part by weight of microcrystalline cellulose are placed in a fluidised bed; e) the solution of step c) comprising coenzyme Q10 and HPMC is sprayed onto the fluidised bed to form a granular powder; f) the granules of step e) are mixed with magnesium stearate; and g) the resultant granules of step f) are filled into a capsule, pressed into a tablet or filled into a granules bag.General method for manufacturing granules with PEG 10000 to 22000, poloxamer and docusate sodium

[0194] The following embodiments illustrate methods for manufacturing the composition of the invention including in the form of granules and tablets in accordance with the present invention. a) 1 part by weight of coenzyme Q10 raw material is dissolved in 2 to 6 parts by weight of an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol dichloromethane or trichloromethane until it is fully dissolved; b) 1 to 3 parts by weight of PEG 1000 to 22000, 1 to 3 parts by weight of poloxamer, and 1 part by weight of docusate sodium are dissolved in 3 to 10 parts by weight of an alcohol selected from ethanol, isopropanol or benzyl alcohol until fully dissolved; c) the coenzyme Q10 solution of step a) and the resultant solution of step b) are mixed together; d) 1 part by weight of crosslinked sodium carboxymethyl cellulose, 1 part by weight of crosslinked povidone, 1 part by weight of microcrystalline cellulose are placed in a fluidised bed; e) the solution of step c) is sprayed onto the fluidised bed to form a granular powder; f) 8% PVPK30 solution is sprayed onto the fluidised bed to bind the powder together to give granules; g) the granules of step f) are mixed with magnesium stearate; and h) the resultant granules of step g) are filled into a capsule, pressed into a tablet or filled into a granules bag.General method for manufacturing granules with PEG and poloxamer

[0195] The following embodiments illustrate methods for manufacturing the composition of the invention including in the form of granules, tablets and capsules in accordance with the present invention. a) 1 part by weight of coenzyme Q10 raw material is dissolved in 2 to 6 parts by weight of an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol dichloromethane or trichloromethane until fully dissolved; b) 1 to 3 parts by weight of PEG 1000 to 22000 and 1 to 2 parts by weight of poloxamer are dissolved in 3 to 12 parts by weight of an alcohol selected from ethanol, isopropanol or benzyl alcohol until fully dissolved; c) the coenzyme Q10 solution of step a) and the PEG / poloxamer solution of step b) are mixed together; d) 1 to 2 parts by weight of crosslinked sodium carboxymethyl cellulose, 1 to 2 parts by weight of cross-linked povidone are placed in a fluidised bed; e) the solution of step c) comprising coenzyme Q10, poloxamer and PEG 1000 to 22000 is sprayed onto the fluidised bed to form a granular powder; f) 8% PVPK30 solution is sprayed onto the fluidised bed to bind the powder together to give granules; g) the granules of step f) are mixed with magnesium stearate; and h) the resultant granules of step g) are filled into a capsule, pressed into a tablet or filled into a granules bag.General method of treating coenzyme Q10 deficiency

[0196] An embodiment of the invention relates to administration of compositions of the invention as disclosed herein to treat coenzyme Q10 deficiency, or conditions related to coenzyme Q10 deficiency, including e.g. heart failure, cardiomyopathy or myopathy.

[0197] In some embodiments, the amount of coenzyme Q10 in the composition of the invention, when used to treat coenzyme Q10 deficiency, is from about 5 mg to 150 mg per tablet. In some embodiments, the dosage amount of coenzyme Q10 in the composition of the invention, when used to treat heart failure, cardiomyopathy or myopathy is from about 5 mg to 150 mg daily.EXAMPLES

[0198] The present invention will now be illustrated by the following examples which are not to be construed as limiting the present invention in any manner and are only examples of the various formulations described herein.

[0199] A capsule containing 150 mg of coenzyme Q10 was subject to a dissolution test. The dissolution amount from stirring the composition at 75 RPM at 2 hours in 1000 mL of 0.5% Triton (surfactant) aqueous solution was 26 mg or 17.3%.

[0200] Another prior art composition is BLACKMORES 150 mg coenzyme Q10 soft capsule, which was also subject to dissolution. The dissolution amount (using batch number 31185) from stirring at 75 RPM at 2 hours in 1000 mL of 0.5% Triton buffered at pH 4.5 with sodium acetate was 14 mg or 9.3%. At 3 hour of stirring, the dissolution amount was about 26 mg, indicating that the soft capsules do not improve the dissolution of coenzyme Q10.

[0201] Additional dissolution tests were conducted using BLACKMORES 150 mg coenzyme Q10 soft capsule (batch number 31185) and stirred at 75 RPM in 1000 mL of 0.5% Triton aqueous solutions with different buffering conditions to give the following results:

[0202] 150 mg (30 mg x 5) coenzyme Q10 soft capsules (of lot number 20211105) from Dongying Zouning Biotechnology were also subject to a dissolution test. The capsules were stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton with 0.1% Tween 80 aqueous solution to give a dissolution amount of 0.2%.

[0203] A representative dissolution protocol that may be used in accordance with the present invention is as follows: a composition comprising 150 mg coenzyme Q10 spheres is stirred at 75 RPM for 2 hours in 1000 mL of 0.5% Triton buffered at pH 4.5 with sodium acetate and provided a dissolution amount of 145 mg.EXAMPLE 1: Formulation and dissolution of coenzyme Q10 spheres in 1000 mL of 0.5% Triton aqueous solution buffered at pH 4.5 with sodium acetate

[0204] A coenzyme Q10 capsule comprising 150 mg of coenzyme Q10 was prepared according to the following method: a) 1500 g of coenzyme Q10 raw material was dissolved in 3000 g of acetone; b) 1500 g of HPMC (E5) was dissolved in 4950 g of ethanol; c) the solution of step a) and the solution of step b) were mixed together to form a solution; d) 3000 g of sucrose cores (of 0.5 mm to 0.71 mm diameter) were placed into a fluidised bed; e) the mixture of step c) was sprayed onto the fluidised bed; f) the material on the fluidised bed was cooled until the temperature was <35°C to give a product in the form of spheres or pellets;g) the sphere or pellets of step f) are filled into a capsules or pellet bag.

[0205] The coenzyme Q10 dissolution of the composition of batch number 220824 was the highest, but the amount of spheres was too large to be filled into a capsule. However, the spheres could be filled into a pellet bag.

[0206] The following 5 examples used a similar method of production as described above, but comprise different ratios of reagents, resulting in different dissolution amounts as shown below:EXAMPLE 2: Formulation of coenzyme Q10 granules and 90 mg tablet using fluidised bed granulation:

[0207] Coenzyme Q10 granules and 90 mg tablets were prepared according to the following procedure: a) 540 g of coenzyme Q10 raw material was dissolved in 1080 g of acetone; b) 1080 g of HPMC was dispersed in 7200 g of water; c) the solution of step a) and the mixture of step b) were mixed together to form a mixture;d) 180 g of lactose, 720 g of cross-linked povidone and 360 g of microcrystalline cellulose were placed in a fluidised bed; e) the mixture of step c) comprising coenzyme Q10 and HPMC was sprayed onto the fluidised bed; f) 8% PVPK30 solution was sprayed onto the fluidised bed to give granules; g) the granules of step f) were mixed with magnesium stearate; and the resulting granules were pressed into a tablet, wherein the tablet comprises 90 mg of coenzyme Q10.

[0208] Coenzyme Q10 granules and tablets (each comprising 90 mg of coenzyme Q10) were subjected to a dissolution test by stirring at 75 RPM in 1000 mL of 0.5% Triton aqueous solution buffered at pH 4.5 with sodium acetate to provide the following results:

[0209] The dissolution of the tablets was lower than the granules of the invention. The dissolution of both coenzyme Q10 granules and tablets was poorer than coenzyme Q10 spheres of the invention.EXAMPLE 3: Formulation of 45 mg coenzyme Q10 granules and tablet

[0210] Coenzyme Q10 tablets and granules (each comprising 45 mg of coenzyme Q10) were subjected to a dissolution test by stirring at 75 RPM in 1000 mL of 0.5% Triton aqueous solution to provide the following results:EXAMPLE 4: Formulation of granules and a tablet comprising 45 mg coenzyme Q10 and 90 mgPEG 6000

[0211] Coenzyme Q10 tablets and granules (each comprising 45 mg of coenzyme Q10) were subjected to a dissolution test by stirring at 75 RPM in 1000 mL of 0.5% Triton aqueous solution to provide the following results:EXAMPLE 5: Formulation and dissolution of coenzyme Q10 tablets in 1000 mL of 0.5% Triton and 0. 1% Tween 80 agueous solution

[0212] A coenzyme Q10 tablet comprising 30 mg of coenzyme Q10 was prepared according to the following method: a) 300 g of coenzyme Q10 raw material, 900 g sorbitol, 120 g egg lecithin, and 900 g malic acid were dissolved in 7800 g of acetone; b) 300 g cross-linked povidone, 300 g croscarmellose sodium, and 300 g lauryl sodium sulfate were placed into a fluidised bed; c) the solution of step a) was sprayed onto the fluidised bed; d) 3% PVPK30 solution was sprayed onto the fluidised bed to give granules;e) the granules of step d) were mixed with magnesium stearate and talcum powder; and the resulting granules were pressed into a tablet, wherein the tablet comprises 30 mg of coenzyme Q10.

[0213] Coenzyme Q10 granules and tablets (each comprising 30 mg of coenzyme Q10) were subjected to a dissolution test by stirring at 75 RPM in 1000 mL of 0.5% Triton and 0.1% Tween 80 aqueous solution to provide the following results:EXAMPLE 6: Formulation and dissolution of coenzyme Q10 capsules in 1000 mL of 0.5% Triton aqueous solution

[0214] A coenzyme Q10 capsule comprising 150 mg of coenzyme Q10 was prepared according to the following method: a) 1500 g of coenzyme Q10 raw material and 1500g citric acid were dissolved in 39000 g of acetone; b) HPMC (E5) was dissolved in 5000 g of ethanol; c) the solution of step a) and the solution of step b) were mixed together to form a solution; d) 700 g lactose, 600 g microcrystalline cellulose, and 700 g sorbitol were placed into a fluidised bed; e) the mixture of step c) was sprayed onto the fluidised bed; f) 2.4% PVPK30 solution was sprayed onto the fluidised bed to give granules; g) the material on the fluidised bed was cooled until the temperature was <35°C to give a product in the form of spheres or pellets; h) spheres or pellets of g) were mixed with magnesium stearate and talcum powder; and theresulting granules were passed through 24 mesh and then filled into a capsule.

[0215] Coenzyme Q10 capsules (each comprising 150 mg of coenzyme Q10) were subjected to a dissolution test by stirring at 75 RPM in 1000 mL of 0.5% Triton aqueous solution to provide the following results:

Claims

CLAIMS:

1. A composition comprising coenzyme Q10 and one or more water soluble excipients selected from HPMC, PEG, docusate sodium, poloxamer, organic acid and polysorbate, wherein the composition has a dissolution amount of coenzyme Q10 in an aqueous medium of greater than 60%.

2. The composition according to claim 1, wherein the composition has a dissolution amount of coenzyme Q10 of greater than 60%, 70%, 80%, or 90%, in 1000 mL of an aqueous medium of 0.5% Triton of pH 4.5.

3. The composition according to claim 1, wherein the composition is in the form of spheres comprising coenzyme Q10, a binder comprising HPMC of low molecular mass and a core comprising one or more excipients.

4. The composition according to any one of claims 1 to 3, wherein the HPMC is of a molecular mass equal to or lower than 26,000 g / mol.

5. The composition according to claim 2 or 3, wherein the composition comprises a HPMC and coenzyme Q10 mixture coating on the surface of the core, wherein the core comprises sugar, microcrystalline cellulose or a mixture thereof.

6. The composition according to any one of claims 1 to 5, wherein the core comprises one or more of sugar, microcrystalline cellulose, lactose, starch, mannitol, sorbitol, fructose-1,6- diphosphate, and cross-linked povidone, or a mixture thereof.

7. The composition according to claim 1, wherein the composition comprises coenzyme Q10 and PEG 200 to 22000, wherein the composition is in the form of a liquid, granules, a tablet or a capsule.

8. The composition according to claim 1 or 7, wherein the composition comprises 1 part of coenzyme Q10 and 1 to 4 parts of PEG 1000 to 22000 by weight.

9. The composition according to claim 8, further comprising a filler, an expander and a lubricating excipient.

10. The composition according to claim 1 or 7, wherein the composition comprises 1 part of coenzyme Q10 and 1 to 10 parts of PEG 200 to 600 by weight.

11. The composition according to claim 1 or 7, wherein the composition comprises by weight 1 part of coenzyme Q10, 1 to 10 parts of organic acid selected from malic acid, maleic acid, tartaric acid, succinic acid, citric acid and ascorbic acid.

12. The composition according to claim 1, wherein the composition is in the form of granules, tablets or capsules comprising coenzyme Q10 and poloxamer.

13. The composition according to claim 12, wherein the composition comprises 1 part of coenzyme Q10 and 1 to 4 parts of poloxamer.

14. The composition according to claim 1, wherein the composition comprises coenzyme Q10, PEG 1000 to 22000 and poloxamer, wherein the composition is in the form of granules, tablets or capsules.

15. The composition according to claim 14, wherein the composition comprises 1 part of coenzyme Q10, 1 to 3 parts of PEG 1000 to 22000, 1 to 3 parts of poloxamer by weight.

16. The composition according to claim 15, further comprising a filler, an expander and a lubricating excipient.

17. The composition according to claim 1, wherein the composition comprises 1 part of coenzyme Q10 and 0.5 to 3 parts of docusate sodium by weight.

18. The composition according to claim 1, wherein the composition comprises 1 part of coenzyme Q10, 1 to 3 parts of PEG 1000 to 22000, 1 to 3 parts of poloxamer and 0.5 to 1 parts of docusate sodium by weight and the formulation further comprises a filler, an expander and a lubricating excipient.

19. The composition according to claims 1, wherein the composition is in the form of a sphere comprising by weight 1 part of coenzyme Q10, 0.5 to 3 parts of HPMC of low molecular mass and 0.5 to 1 part of a core comprising sugar, microcrystalline cellulose or a mixture thereof.

20. The composition according to claim 1, wherein the composition is in the form of granules or capsules comprising coenzyme Q10 and HPMC of low molecular mass, wherein the composition further comprises one or more of lactose, sugar, microcrystalline cellulose, and cross-linked povidone, or a mixture thereof.

21. A method of producing a coenzyme Q10 composition in the form of a sphere, the method comprising the steps of: a) dissolving 1 part by weight of coenzyme Q10 in an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol, dichloromethane or trichloromethane, until the coenzyme Q10 is fully dissolved; b) dissolving 0.5 to 3 parts by weight of HPMC of low molecular mass in a solvent selected from ethanol, isopropyl alcohol or benzyl alcohol; c) mixing the solution of step a) and the solution of step b) together to form a solution comprising coenzyme Q10 and HPMC; and d) spraying the coenzyme Q10 and HPMC solution of step c) onto cores on a fluidised bed, wherein the cores comprise sugar, microcrystalline cellulose or a mixture thereof, to form a sphere containing coenzyme Q10, HPMC and a core.

22. A method of producing a coenzyme Q10 composition, wherein the method comprises the steps of: a) dissolving 1 part by weight of coenzyme Q10 in an organic solvent selected from acetone, butanone, pentanone, ethanol, isopropyl alcohol, benzyl alcohol, dichloromethane or trichloromethane until the coenzyme Q10 is fully dissolved or dispersed; b) adding 1 to 3 parts of PEG 1000 to 22000, 1 to 3 part of poloxamer or 0.5 to 1 parts of docusate sodium by weight into the solution or dispersion of step a) until the PEG, poloxamer or docusate sodium is fully dissolved or dispersed; c) placing 1 part each of lactose, sugar, microcrystalline cellulose, cross-linked povidone in a fluidised bed; d) spraying the solution or dispersion of step b) onto the fluidised bed to form a powdered mixture; e) spraying a PVP K30 solution into the fluidised bed of step d) to form granules; and f) mixing the granules of step e) with a lubricating agent, preferably magnesium stearate, and compressing the granules into a tablet or filling the granules into a capsule or granule bag.

23. The composition according to any one of claims 1 to 20 for use in providing heart nutrients to a patient with heart disease.

24. Use of the composition of any one of claims 1 to 20 in the manufacture of a medicament for treating coenzyme Q10 deficiency or a condition related to coenzyme Q10 deficiency, such as heart failure, cardiomyopathy or myopathy, wherein the composition is formulated for administration of 300 mg of coenzyme Q10 to a patient daily.

25. A method of treating coenzyme Q10 deficiency or a condition related to coenzyme Q10 deficiency, such as heart failure, cardiomyopathy or myopathy comprising administering to a subject the composition of any one of claims 1 to 20, wherein the composition is formulated for administration of 300 mg of coenzyme Q10 to a patient daily.

Citation Information

Patent Citations

  • Stabilized preparation containing Coenzyme Q10 and Process for Preparation Thereof

    KR100982130B1

  • Solid pharmaceutical composition for enhanced delivery of coenzyme q-10 and ubiquinones

    US20090060993A1